AP3170A - New CCR2 receptor antagonists and uses thereof - Google Patents

New CCR2 receptor antagonists and uses thereof

Info

Publication number
AP3170A
AP3170A AP2012006276A AP2012006276A AP3170A AP 3170 A AP3170 A AP 3170A AP 2012006276 A AP2012006276 A AP 2012006276A AP 2012006276 A AP2012006276 A AP 2012006276A AP 3170 A AP3170 A AP 3170A
Authority
AP
ARIPO
Prior art keywords
receptor antagonists
ccr2 receptor
new ccr2
new
antagonists
Prior art date
Application number
AP2012006276A
Other languages
English (en)
Other versions
AP2012006276A0 (en
Inventor
Kai Gerlach
Marco Santagostino
Christoph Hoenke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2012006276A0 publication Critical patent/AP2012006276A0/xx
Application granted granted Critical
Publication of AP3170A publication Critical patent/AP3170A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AP2012006276A 2009-12-17 2010-12-13 New CCR2 receptor antagonists and uses thereof AP3170A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09179555 2009-12-17
EP10162621 2010-05-12
PCT/EP2010/069549 WO2011073154A1 (en) 2009-12-17 2010-12-13 New ccr2 receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
AP2012006276A0 AP2012006276A0 (en) 2012-06-30
AP3170A true AP3170A (en) 2015-03-31

Family

ID=43533115

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2012006276A AP3170A (en) 2009-12-17 2010-12-13 New CCR2 receptor antagonists and uses thereof

Country Status (36)

Country Link
US (6) US8765949B2 (pl)
EP (3) EP2813503B1 (pl)
JP (1) JP5632014B2 (pl)
KR (1) KR101530234B1 (pl)
CN (1) CN102933579B (pl)
AP (1) AP3170A (pl)
AR (1) AR079636A1 (pl)
AU (1) AU2010332969B2 (pl)
BR (1) BR112012015873B1 (pl)
CA (1) CA2782464C (pl)
CL (1) CL2012001311A1 (pl)
CO (1) CO6650336A2 (pl)
CY (1) CY1115873T1 (pl)
DK (1) DK2513093T3 (pl)
EA (1) EA024397B1 (pl)
EC (1) ECSP12012010A (pl)
ES (2) ES2674275T3 (pl)
GE (1) GEP20146124B (pl)
HR (1) HRP20141143T1 (pl)
IL (1) IL219421A (pl)
MA (1) MA33818B1 (pl)
ME (1) ME01908B (pl)
MX (2) MX2012006964A (pl)
MY (1) MY160471A (pl)
NZ (1) NZ599770A (pl)
PE (1) PE20121614A1 (pl)
PH (1) PH12012501215A1 (pl)
PL (2) PL3091012T3 (pl)
PT (2) PT2513093E (pl)
RS (1) RS53555B1 (pl)
SG (1) SG181722A1 (pl)
SI (1) SI2513093T1 (pl)
TN (1) TN2012000300A1 (pl)
TW (1) TWI473800B (pl)
UY (1) UY33109A (pl)
WO (1) WO2011073154A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
WO2012171863A1 (en) * 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
EP2731941B1 (en) * 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
US20140329809A1 (en) 2011-10-28 2014-11-06 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids
WO2016081801A1 (en) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Use of an anti-ccr2 antagonist in the treatment of an infectious disease
DK3297438T3 (da) 2015-05-21 2022-01-17 Chemocentryx Inc Ccr2-modulatorer
PT3317270T (pt) * 2015-07-02 2020-08-24 Centrexion Therapeutics Corp (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona
JP2019517523A (ja) 2016-06-03 2019-06-24 ケモセントリックス， インコーポレイテッド 肝線維症を治療する方法
WO2017218544A1 (en) * 2016-06-13 2017-12-21 Chemocentryx, Inc. Methods of treating pancreatic cancer
US10195188B2 (en) 2016-06-13 2019-02-05 Chemocentryx, Inc. Method of treating pancreatic cancer
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
RU2765737C2 (ru) 2016-11-23 2022-02-02 Хемоцентрикс, Инк. Способ лечения фокально-сегментарного гломерулосклероза
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3293051A1 (en) 2017-09-25 2026-03-02 Chemocentryx, Inc. Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
RU2020113612A (ru) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
US20210322412A1 (en) * 2020-04-20 2021-10-21 Centrexion Therapeutics Corporation Methods and compositions for treating a coronavirus infection
NL2026714B1 (en) * 2020-10-20 2022-06-16 Lumicks Ca Holding B V Improved detection of lymphocyte - target cell interaction

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US213428A (en) * 1879-03-18 Improvement in harrow-teeth
US568885A (en) * 1896-10-06 Can-seaming mechanism
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4426382A (en) 1980-02-13 1984-01-17 Sankyo Company Limited 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DE3517617A1 (de) 1985-05-15 1986-11-20 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Neue pyridaziniumverbindungen, verfahren zu deren herstellung und diese enthaltende fungizide und algizide mittel
JPS6319745Y2 (pl) 1985-11-07 1988-06-01
JPS61165445A (ja) 1986-01-08 1986-07-26 株式会社巴組鐵工所 振動を減少しうる床構造
US5096916A (en) 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
DE69325662T2 (de) 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon Dopamin rezeptor subtyp liganden
JP3166376B2 (ja) 1993-02-03 2001-05-14 松下電器産業株式会社 熱利用装置
US5629235A (en) 1995-07-05 1997-05-13 Winbond Electronics Corporation Method for forming damage-free buried contact
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EE04588B1 (et) 1997-10-27 2006-02-15 Neurosearch A/S Heteroarüüldiasatsükloalkaanid kui atsetüülkoliini nikotiinretseptorite kolinergilised ligandid, nende kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
US6143892A (en) 1998-11-20 2000-11-07 G. D. Searle & Co. Process for making 5-substituted pyrazoles
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
SK287418B6 (sk) 1999-05-04 2010-09-07 Schering Corporation Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US20020045613A1 (en) 2000-04-27 2002-04-18 Heinz Pauls 1-aroyl-piperidinyl benzamidines
OA12274A (en) 2000-05-22 2006-05-09 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors.
WO2002030928A1 (de) 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kristallines monohydrat, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
ME00412B (me) 2001-06-22 2011-10-10 Boehringer Ingelheim Pharma Kristalni antiholinergik , postupak za njegovo pripremanje i njegova primjena u proizvodnji lijeka
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
EP1474401A2 (en) 2002-02-05 2004-11-10 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
JP2003240776A (ja) 2002-02-13 2003-08-27 Horiba Ltd クロマトグラフリーダを用いる測定方法およびそれに用いる試験片ホルダ並びにクロマトグラフリーダを用いる検査／測定装置
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CN100445276C (zh) 2002-03-13 2008-12-24 詹森药业有限公司 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20050245537A1 (en) 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
EP1501507B1 (en) 2002-04-29 2008-05-28 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
TW200400960A (en) 2002-06-05 2004-01-16 Pharmacia Corp Novel pyrazoles and their use as P38 kinase inhibitors
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US20040147561A1 (en) 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2004074438A2 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CA2523431A1 (en) 2003-04-23 2004-11-25 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
JP2006528147A (ja) 2003-07-18 2006-12-14 グラクソ　グループ　リミテッド ヒスタミンｈ３受容体リガンドとしての置換ピペリジン
WO2005009976A1 (en) 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
KR20080052683A (ko) 2003-12-18 2008-06-11 인사이트 코포레이션 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
US7435830B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
US7423147B2 (en) 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2006001958A2 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
CA2569016C (en) 2004-06-02 2012-11-27 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
FR2871157A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Produits biaryl aromatiques, compositions les contenant et utilisation
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006012135A1 (en) 2004-06-24 2006-02-02 Janssen Pharmaceutica, N. V. Quaternary salt ccr2 antagonists
WO2006004741A2 (en) * 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CN1976702A (zh) * 2004-06-28 2007-06-06 因赛特公司 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
JP2008510783A (ja) 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド ４−ヘテロアリールメチル置換フタラジノン誘導体
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
CA2589106C (en) 2004-11-02 2015-07-21 Northwestern University Pyridazine compounds, compositions and methods and their use in treating inflammatory diseases
PA8653301A1 (es) 2004-11-22 2006-11-09 Incyte Corp Incyte Corp Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin
DE102004061751A1 (de) 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidin-substituierte Pyrazoline
TWI385164B (zh) 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
JP2008537953A (ja) 2005-04-15 2008-10-02 エラン ファーマシューティカルズ，インコーポレイテッド ブラジキニンｂ１受容体拮抗作用に有用な新規化合物
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
EP2354140A1 (en) 2005-05-20 2011-08-10 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
US7851474B2 (en) 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR055203A1 (es) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd Derivados de benzotiofeno con propiedades antipsicoticas
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
KR101415426B1 (ko) 2005-09-27 2014-07-04 아이알엠 엘엘씨 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007053495A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
CN101309915A (zh) 2005-11-14 2008-11-19 Irm责任有限公司 作为lxr调节剂的化合物和组合物
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
IL172838A (en) 2005-12-27 2010-06-16 Joma Int As Methods for production of metal oxide nano particles with controlled properties and nano particles and preparations produced thereby
WO2007084868A2 (en) 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
NZ570847A (en) 2006-02-28 2011-10-28 Helicon Therapeutics Inc Therapeutic compounds
WO2007105058A2 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007120574A2 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Diaryl substituted alkanes
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20100168120A1 (en) 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
US20080039450A1 (en) 2006-06-22 2008-02-14 Jensen Annika J Compounds
CA2657247A1 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
GB0617575D0 (en) 2006-09-06 2006-10-18 Syngenta Ltd Herbicidal compounds and compositions
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CN101534824A (zh) 2006-11-17 2009-09-16 艾博特公司 作为化学活素受体拮抗剂的氨基吡咯烷
ES2548353T3 (es) 2006-12-28 2015-10-15 Abbvie Inc. Inhibidores de poli(ADP-ribosa)polimerasa
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
FR2915552B1 (fr) 2007-04-27 2009-11-06 Technip France Conduite tubulaire flexible pour le transport d'hydrocarbures gazeux.
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
CA2691662A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag Imidazole derivatives as ccr2 receptor antagonists
US7977358B2 (en) 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
MX2010002005A (es) 2007-08-22 2010-03-11 Irm Llc Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
RU2010116821A (ru) 2007-10-01 2011-11-10 Ф.Хоффманн-Ля Аг (Ch) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr
RU2487127C2 (ru) 2007-10-09 2013-07-10 Ф.Хоффманн-Ля Рош Аг Хиральные цис-имидазолины
CN101820789A (zh) 2007-10-12 2010-09-01 黄钟午 鞋带捆绑工具
US20090131417A1 (en) 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
WO2009066084A1 (en) 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
EP2062889A1 (de) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
AU2009259496A1 (en) 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
JP5693452B2 (ja) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビター、医薬組成物およびそれらの使用方法
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2009289378A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
CA2737639A1 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
CN102256963B (zh) 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
US20110301143A1 (en) 2009-02-23 2011-12-08 Elise Isabel Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2674275T3 (es) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation Antagonistas del receptor CCR2 y usos de los mismos
EP2513086B1 (en) * 2009-12-17 2015-04-29 Boehringer Ingelheim International GmbH Novel antagonists for ccr2 and uses thereof
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5646736B2 (ja) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
WO2012171863A1 (en) 2011-06-16 2012-12-20 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
JP6229575B2 (ja) 2014-03-31 2017-11-15 京セラドキュメントソリューションズ株式会社 画像処理装置
PT3317270T (pt) * 2015-07-02 2020-08-24 Centrexion Therapeutics Corp (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona

Also Published As

Publication number Publication date
EP2513093B1 (en) 2014-08-27
NZ599770A (en) 2014-06-27
JP2013514301A (ja) 2013-04-25
US20190300541A1 (en) 2019-10-03
TWI473800B (zh) 2015-02-21
UY33109A (es) 2011-07-29
US20120004252A1 (en) 2012-01-05
ECSP12012010A (es) 2012-08-31
AU2010332969B2 (en) 2015-02-12
MY160471A (en) 2017-03-15
US20170362249A1 (en) 2017-12-21
HRP20141143T1 (hr) 2015-01-02
MA33818B1 (fr) 2012-12-03
TN2012000300A1 (en) 2013-12-12
MX2012006964A (es) 2012-07-17
WO2011073154A1 (en) 2011-06-23
SI2513093T1 (sl) 2014-11-28
KR20120123652A (ko) 2012-11-09
AP2012006276A0 (en) 2012-06-30
CA2782464C (en) 2016-11-29
CA2782464A1 (en) 2011-06-23
AR079636A1 (es) 2012-02-08
US11731981B2 (en) 2023-08-22
IL219421A (en) 2015-07-30
DK2513093T3 (da) 2014-09-29
RS53555B1 (sr) 2015-02-27
KR101530234B1 (ko) 2015-06-19
PL3091012T3 (pl) 2018-08-31
US12209094B2 (en) 2025-01-28
EA024397B1 (ru) 2016-09-30
SG181722A1 (en) 2012-07-30
CN102933579B (zh) 2015-07-15
CY1115873T1 (el) 2017-01-25
IL219421A0 (en) 2012-06-28
CO6650336A2 (es) 2013-04-15
GEP20146124B (en) 2014-07-25
EP3091012A1 (en) 2016-11-09
EP2813503B1 (en) 2016-04-20
PT3091012T (pt) 2018-06-27
AU2010332969A1 (en) 2012-05-31
ES2674275T3 (es) 2018-06-28
PE20121614A1 (es) 2012-12-21
EP3091012B1 (en) 2018-04-11
ES2524829T3 (es) 2014-12-12
US10196402B2 (en) 2019-02-05
US20220002310A1 (en) 2022-01-06
PL2513093T3 (pl) 2015-03-31
BR112012015873A2 (pt) 2019-09-24
HK1178147A1 (en) 2013-09-06
EP2813503A1 (en) 2014-12-17
ME01908B (me) 2014-12-20
JP5632014B2 (ja) 2014-11-26
TW201130816A (en) 2011-09-16
CN102933579A (zh) 2013-02-13
EP2513093A1 (en) 2012-10-24
EA201200876A1 (ru) 2013-01-30
PT2513093E (pt) 2014-10-22
MX346393B (es) 2017-03-17
CL2012001311A1 (es) 2012-10-12
PH12012501215A1 (en) 2015-11-13
US20240109909A1 (en) 2024-04-04
US8765949B2 (en) 2014-07-01
US20140235661A1 (en) 2014-08-21
US11046706B2 (en) 2021-06-29
BR112012015873B1 (pt) 2021-06-01
US9670222B2 (en) 2017-06-06

Similar Documents

Publication Publication Date Title
AP3170A (en) New CCR2 receptor antagonists and uses thereof
ZA201202029B (en) Androgen receptor antagonists and uses thereof
IL229507A0 (en) Extrinsic opioid receptor antagonists and their uses
ZA201203452B (en) Cgrp receptor antagonists
ZA201105323B (en) Agonists and antagonists of the sip5 receptor,and methods of uses thereof
ZA201103156B (en) Isonicotinamide orexin receptor antagonists
IL218502A0 (en) Actriib antagonists and dosing and uses thereof
PT2927224T (pt) Antagonistas de receptores
PL2137191T3 (pl) Antagoniści obwodowego receptora opioidowego i ich zastosowania
SG10201404662YA (en) Dp2 antagonist and uses thereof
HRP20150661T1 (en) Peripheral opioid receptor and antagonists and uses thereof
IL201165A0 (en) CRIg ANTAGONISTS
ZA201105056B (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
IL217965A0 (en) Bicyclic heterocycles and their use as ccr2 receptor antagonists
GB0701632D0 (en) MET receptor antagonists
GB0901836D0 (en) EP4 receptor antagonists
GB0900756D0 (en) EP4 Receptor antagonists
GB0900755D0 (en) Ep4 receptor antagonists
GB0900754D0 (en) EP4 Receptor antagonists
GB0705802D0 (en) Novel receptor antagonists and their methods of use
GB0709038D0 (en) Novel receptor antagonists and their methods of use